Which Patients Can Benefit More from ADC Treatment?
Introduction In the field of cancer treatment, antibody-drug conjugates (ADCs) are hailed as “biological missiles” that can precisely deliver high concentrations of chemotherapy drugs to tumor cells, enhancing efficacy while reducing damage to normal tissues. Among them, trastuzumab deruxtecan (T-DXd, also known as DS-8201), which targets the HER2 protein, has become a significant breakthrough in … Read more